Vaxart (OTCMKTS:VXRT) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Vaxart (OTCMKTS:VXRT) issued its earnings results on Thursday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.04), Zacks reports. Vaxart had a net margin of 15.88% and a return on equity of 53.04%. The company had revenue of $10.62 million during the quarter, compared to analyst estimates of $27.20 million.

Vaxart Stock Performance

Vaxart stock traded down $0.02 during mid-day trading on Friday, reaching $0.38. 18,299 shares of the company were exchanged, compared to its average volume of 474,530. The firm’s 50-day simple moving average is $0.46 and its two-hundred day simple moving average is $0.58. Vaxart has a twelve month low of $0.33 and a twelve month high of $0.84. The firm has a market cap of $93.22 million, a PE ratio of 2.39 and a beta of 1.15.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Vaxart to a “hold” rating in a research note on Thursday, July 9th. One analyst has rated the stock with a Hold rating. According to MarketBeat.com, the stock presently has a consensus rating of “Hold”.

About Vaxart

Vaxart, Inc is a biotechnology company focused on developing oral recombinant vaccines delivered in tablet form. Its proprietary platform is designed to stimulate immune responses at mucosal surfaces, such as those in the nose and mouth, in addition to generating systemic immunity. The company’s approach is intended to offer a needle-free alternative to traditional injectable vaccines.

Vaxart’s development programs have included oral vaccine candidates for coronavirus infections, norovirus and influenza.